These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 8965633)

  • 1. [Reactivity and immunogenicity of Havrix 360 vaccine for hepatitis A].
    Borcić B; Kovac S; Mihaljević I; Dobrovsak-Sourek V; Ljubicić M
    Lijec Vjesn; 1996; 118(7-8):162-4. PubMed ID: 8965633
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Protection of adolescents against hepatitis A].
    Puntarić D; Baklaić Z; Ljubicíc M; Vodopija I
    Lijec Vjesn; 1996 Oct; 118(10):241-3. PubMed ID: 9132523
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity, safety, and interchangeability of two inactivated hepatitis A vaccines in Chilean children.
    Abarca K; Ibánez I; Perret C; Vial P; Zinsou JA
    Int J Infect Dis; 2008 May; 12(3):270-7. PubMed ID: 17988917
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity and safety of an inactivated hepatitis A vaccine amongst Singaporeans.
    Guan R; Ng HS; Fock KM; Ho KY; Yap I; Kang JY; Chow WC; Chew CN; Ng C; Teo CJ
    Southeast Asian J Trop Med Public Health; 1995 Jun; 26(2):268-71. PubMed ID: 8629058
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical trial to evaluate immunogenicity and safety of inactivated hepatitis A vaccination starting at 2-month-old children.
    Kanra G; Yalçin SS; Ceyhan M; Yurdakök K
    Turk J Pediatr; 2000; 42(2):105-8. PubMed ID: 10936974
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inactivated hepatitis A vaccine: reactogenicity, immunogenicity, and long-term antibody persistence.
    Van Damme P; Thoelen S; Cramm M; De Groote K; Safary A; Meheus A
    J Med Virol; 1994 Dec; 44(4):446-51. PubMed ID: 7897379
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single dose-inactivated hepatitis A vaccination schedule for susceptible youngsters.
    Lee SD; Chan CY; Yu MI; Wang YJ; Lo KJ; Safary A
    Am J Gastroenterol; 1996 Jul; 91(7):1360-2. PubMed ID: 8677995
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A trial of the reactogenicity and immunogenicity of an inactivated hepatitis A vaccine.
    Green MS; Cohen D; Lerman Y; Sjogren M; Binn LN; Zur S; Slepon R; Robin G; Hoke C; Bancroft W
    Isr J Med Sci; 1994; 30(5-6):485-8. PubMed ID: 8034508
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of the antibody response in humans with a new inactivated hepatitis A vaccine.
    Vidor E; Xueref C; Blondeau C; Bajard A; Francon A; Goudeau A; Peyron F; Brasseur P; Zuckerman A
    Biologicals; 1996 Sep; 24(3):235-42. PubMed ID: 8978923
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mathematical models for assessment of long-term persistence of antibodies after vaccination with two inactivated hepatitis A vaccines.
    Van Herck K; Beutels P; Van Damme P; Beutels M; Van den Dries J; Briantais P; Vidor E
    J Med Virol; 2000 Jan; 60(1):1-7. PubMed ID: 10568755
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity of an inactivated hepatitis A pediatric vaccine: three-year post-booster follow-up.
    Dagan R; Greenberg D; Weber F
    Vaccine; 2005 Oct; 23(44):5144-8. PubMed ID: 16043271
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Evaluation of immunogenicity and safety in healthy adults of an inactivated anti-hepatitis A vaccine].
    Gil A; González A; Dal-Ré ; Aguilar L; Malo C; del Rey J
    Med Clin (Barc); 1994 May; 102(20):769-71. PubMed ID: 8041214
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Safety and immunogenicity of a new inactivated hepatitis A vaccine].
    Ren A; Ma J; Feng F
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2001 Dec; 15(4):357-9. PubMed ID: 11986726
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity and reactogenicity of an inactivated hepatitis A vaccine in Indian adults.
    Das K; Jain A; Gupta RK; Kar P
    Natl Med J India; 1999; 12(6):268-9. PubMed ID: 10732428
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and effectiveness of the new inactivated hepatitis A virus vaccine.
    Furesz J; Scheifele DW; Palkonyay L
    CMAJ; 1995 Feb; 152(3):343-8. PubMed ID: 7828098
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity of hepatitis A vaccine in children with celiac disease.
    Sari S; Dalgic B; Basturk B; Gonen S; Soylemezoglu O
    J Pediatr Gastroenterol Nutr; 2011 Nov; 53(5):532-5. PubMed ID: 21587080
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Reactivity and immunogenicity of Engerix B, the recombinant DNA vaccine against hepatitis B].
    Borcić B; Gasparović V; Mihaljevic I; Aleraj B; Margan IG
    Acta Med Iugosl; 1989; 43(4):247-54. PubMed ID: 2534021
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reactogenicity and immunogenicity of three different lots of a hepatitis A vaccine.
    Theilmann L; Kallinowski B; Gmelin K; Hofmann F; Scheiermann N; Wohland B; Stickl H; Maiwald H; Moriabadi FK; Bock HL
    Vaccine; 1992; 10 Suppl 1():S132-4. PubMed ID: 1335644
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical assessment of the safety and efficacy of an inactivated hepatitis A vaccine: rationale and summary of findings.
    André FE; D'Hondt E; Delem A; Safary A
    Vaccine; 1992; 10 Suppl 1():S160-8. PubMed ID: 1335652
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cell mediated and antibody immune response to inactivated hepatitis A vaccine.
    Schmidtke P; Habermehl P; Knuf M; Meyer CU; Sänger R; Zepp F
    Vaccine; 2005 Oct; 23(44):5127-32. PubMed ID: 16054733
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.